Ryan Specialty Holdings, Inc.
RYAN
$43.68
-1.82%
Ryan Specialty Holdings, Inc. is an international specialty insurance intermediary that provides wholesale brokerage and delegated underwriting authority products and services — including distribution, underwriting, product development, administration, and risk management — to insurance brokers, agents, and carriers across property, casualty, professional lines, transportation, personal lines, workers' compensation, and employee benefits. The company occupies a distinct position as a pure-play specialty intermediary, differentiating itself from broad-based brokers through deep technical underwriting expertise and a delegated authority platform that spans both traditional insurance and alternative risk solutions, with the majority of revenue generated in the United States. The current investor narrative is dominated by a sharp divergence between the company's fundamental trajectory and its equity performance: despite a market capitalization of roughly $11.2 billion and a workforce of over 6,100 employees, the stock has been one of the notable large-cap laggards, with the only recent news headline in the dataset referencing a broad-based selloff across tech, gaming, and real estate that created potential buying opportunities for patient investors. The debate now centers on whether the severe multiple compression reflects a durable de-rating of specialty insurance intermediaries amid a softening rate environment, or an oversold dislocation in a business that analysts still collectively rate as a Buy with a consensus target implying substantial upside.…
RYAN
Ryan Specialty Holdings, Inc.
$43.68
Investment Opinion: Should I buy RYAN Today?
Based on the synthesis of analyst consensus, valuation, and risk factors, RYAN warrants a Hold rating with a speculative bias. The analyst consensus is Buy with an average target of $49.84, implying 34.7% upside, but the recommendation mean of 2.32 (closer to Hold) and the wide target range ($38-$76) indicate moderate conviction. The core thesis is that the market is pricing in a near-total earnings collapse that is unlikely to persist, but the path to recovery is uncertain and the balance sheet is stretched.
Supporting evidence for a Hold includes: 1) Forward PE of 15.16 is well below the 18-22x peer range, suggesting undervaluation if earnings materialize; 2) Revenue is estimated at $3.83 billion, with a gross margin of 90.58% that demonstrates pricing power; 3) Operating margin of 20.49% is healthy, but net margin of 2.08% shows room for improvement; 4) The average analyst target implies 34.7% upside, and even the lowest target is above the current price. However, the 98.33% payout ratio and 5.45 debt-to-equity ratio are red flags that could limit upside if earnings disappoint.
The biggest risks that could invalidate the thesis are: 1) Failure to achieve the forward EPS estimate of $2.70, which would make the forward PE meaningless and expose the stock to further downside; 2) A dividend cut due to unsustainable payout, which would trigger a sell-off; 3) Continued multiple compression if the market de-rates specialty insurance intermediaries. The rating would upgrade to Buy if the company demonstrates two consecutive quarters of improving net margin and reduces debt, or if the stock drops below $30 with no fundamental deterioration. It would downgrade to Sell if forward EPS estimates are revised down significantly or if the dividend is cut. Relative to its own history and peers, RYAN appears undervalued on a forward basis, but the discount is justified by leverage and execution risk.
Sign up to view all
RYAN 12-Month Price Forecast
Ryan Specialty presents a high-risk, high-reward opportunity that is currently in a show-me phase. The stock is deeply discounted on forward earnings, but the discount is justified by razor-thin trailing profitability, high leverage, and an unsustainable dividend payout. The analyst community remains bullish with a $49.84 average target, but the wide range ($38-$76) reflects binary outcomes. The key catalyst is the realization of the forward EPS estimate of $2.70; if achieved, the stock could re-rate toward $55-$76, but failure could send it back to $29. I would upgrade to bullish if the company reports two consecutive quarters of improving net margin and reduces debt, and downgrade to bearish if forward EPS estimates are cut or the dividend is reduced.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Ryan Specialty Holdings, Inc.'s 12-month outlook, with a consensus price target around $49.09 and implied upside of +12.4% versus the current price.
Average Target
$49.09
0 analysts
Implied Upside
+12.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$38 - $76
Analyst target range
Coverage on Ryan Specialty is robust, with 16 analysts contributing to a consensus recommendation of Buy and a recommendation mean of 2.32 (on a scale where lower is more bullish). The average target price of $49.84 implies upside of +34.7% from the current price of $37.01, a substantial gap that signals the sell-side views the recent decline as a dislocation rather than a fundamental deterioration. The consensus is clearly bullish in direction, but the recommendation mean of 2.32 — closer to Hold than to Strong Buy — indicates that conviction is moderate rather than emphatic, consistent with a stock that has badly underperformed and whose earnings inflection remains unproven. The target range is exceptionally wide, spanning from a low of $38.00 to a high of $76.00 — a spread of $38.00, or more than 100% of the current share price. The low target of $38.00 sits just 2.7% above the current price, implying that the most cautious analyst sees the stock as roughly fairly valued and prices in continued margin pressure, integration challenges, and the possibility that the forward EPS estimate of $2.70 proves optimistic. The high target of $76.00 implies upside of +105.3% and would require both multiple expansion and the full realization of the forward earnings inflection, likely accompanied by successful M&A integration, debt reduction, and a re-rating toward peer-group multiples. The wide spread is a classic signal of high uncertainty: when the bull and bear cases differ by more than 2x, it typically means the outcome depends on binary factors — in this case, whether the earnings recovery is real and whether the balance sheet can support it. Notably, the low target of $38.00 is above the current price, meaning no analyst in the coverage universe has a target below the current share price; this is a mildly bullish signal suggesting the sell-off may have overshot, though it also raises the question of whether targets are stale relative to the recent price action. With a short ratio of 7.86, any positive catalyst — a strong earnings print, a debt reduction announcement, or a large M&A deal — could force short covering and accelerate a move toward the consensus target.
Bulls vs Bears: RYAN Investment Factors
The bear case currently has stronger evidence due to the severe technical breakdown, razor-thin trailing profitability, and unsustainable dividend payout. However, the bull case rests on a powerful forward earnings inflection and a deeply discounted forward PE, supported by unanimous analyst upside. The single most important tension is whether the forward EPS estimate of $2.70 is achievable; if it is, the stock is dramatically undervalued, but if it proves optimistic, the valuation support collapses. The wide analyst target range ($38 to $76) underscores the binary nature of this debate. Until the earnings inflection is demonstrated, the stock is likely to remain under pressure, but the high short interest and low expectations set the stage for a sharp reversal on any positive surprise.
Bullish
- Analyst consensus sees 34.7% upside: 16 analysts rate RYAN a Buy with an average target price of $49.84, implying +34.7% upside from the current $37.01. Notably, the lowest target of $38.00 is still 2.7% above the current price, meaning no analyst sees downside from here, which suggests the sell-off may have overshot fundamentals.
- Forward PE of 15.16 is deeply discounted: The forward PE of 15.16 is well below the 18-22x range typical for specialty insurance brokers, implying a 15-30% discount. This discount is hard to justify given the company's 90.58% gross margin and 20.49% operating margin, which are best-in-class for asset-light intermediaries.
- Massive earnings inflection expected: Forward EPS is estimated at $2.70 versus trailing EPS of just $0.0096, implying earnings are expected to roughly septuple. If delivered, this would represent one of the sharpest margin expansions in the sector and would make the current valuation look extremely cheap.
- High short interest could fuel a squeeze: The short ratio of 7.86 means it would take nearly eight days of average volume to cover short positions. With the stock already down 33.47% over the past year, any positive catalyst—such as an earnings beat or debt reduction—could trigger a violent short-covering rally.
Bearish
- Severe underperformance versus the market: RYAN has declined 33.47% over the past year while the S&P 500 gained 16.00%, resulting in a relative strength of -49.47 percentage points. This is one of the worst underperformances in large-cap financials and signals deep investor skepticism.
- Trailing profitability is razor-thin: Trailing net margin is just 2.08% and trailing EPS is $0.0096, far below the 15-25% net margins typical of asset-light insurance brokers. The gap between gross margin (90.58%) and net margin (2.08%) highlights heavy compensation, amortization, and interest costs.
- Dividend payout ratio is unsustainable: The payout ratio of 98.33% means the dividend consumes nearly all trailing earnings, leaving virtually no retained cash for debt reduction or organic investment. This forces reliance on external financing and raises the risk of a dividend cut if earnings disappoint.
- High leverage constrains financial flexibility: Debt-to-equity of 5.45 is elevated and reflects an aggressive M&A strategy funded by debt. With limited free cash flow (PCF ratio of 10.21), servicing this debt while funding growth could strain the balance sheet, especially if the earnings inflection is delayed.
RYAN Technical Analysis
Ryan Specialty is in a sustained downtrend that has been partially interrupted by a volatile recovery attempt. The stock's 1-year price change of -33.47% stands in stark contrast to the S&P 500's +16.00% over the same period, producing a relative strength of -49.47 percentage points — one of the most severe underperformances in the large-cap financials space. At the current price of $37.01, the stock sits at approximately 26.2% of its 52-week range (52-week low of $29.28, 52-week high of $58.94), meaning it is trading in the lower quartile of its annual band. This positioning is ambiguous: it can be read as a value opportunity for contrarians, but the magnitude of the decline and the -49.66% maximum drawdown argue that momentum traders should treat this as a falling knife until a base is confirmed. Recent momentum is negative but decelerating in severity. The 1-month change of -6.19% and 3-month change of -8.41% are both negative, yet the 6-month change is positive at +7.06%, revealing a clear sequence: a powerful rally from the April lows near $29.66 to the late-July peak of $46.48, followed by a steady erosion that has retraced roughly 58% of that advance. The 1-month relative strength versus SPY of -8.31 percentage points confirms the stock is losing ground to the market even as the market itself rallies, which is a bearish divergence. Notably, the 6-month positive return against the 1-year negative return indicates the downtrend is not linear — this is a stock that rallies hard and sells off hard, consistent with a beta of 0.605 that understates the realized volatility of the name. Key technical levels are well defined. Support rests at the 52-week low of $29.28, which also coincides with the early-May capitulation zone around $29.39-$29.66; a breakdown below this area would open the door to a new leg lower and likely trigger further institutional selling. Resistance is layered: the first hurdle is the $40-$42 zone where the stock repeatedly stalled in August and September, followed by the July high of $46.48 and ultimately the 52-week high of $58.94. A breakout above $42 on above-average volume would signal that the base-building phase is complete, while a breakdown below $29.28 would confirm the primary downtrend. The beta of 0.605 implies roughly 40% less volatility than the market on a statistical basis, but the -49.66% max drawdown and the 7.86 short ratio — indicating nearly eight days of average volume needed to cover short positions — suggest that positioning is crowded on the bearish side and that any positive catalyst could produce an outsized short-covering rally.
Beta
0.60
0.60x market volatility
Max Drawdown
-49.7%
Largest decline past year
52-Week Range
$29-$59
Price range past year
Annual Return
-17.8%
Cumulative gain past year
| Period | RYAN Return | S&P 500 |
|---|---|---|
| 1m | +20.8% | -1.0% |
| 3m | +4.6% | +2.9% |
| 6m | +26.2% | +6.5% |
| 1y | -17.8% | +13.1% |
| ytd | -13.7% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
RYAN Fundamental Analysis
Ryan Specialty's revenue trajectory remains one of the more resilient in the specialty insurance intermediary space, with consensus estimated revenue averaging $3.83 billion for the forward period, within a range of $3.62 billion to $3.97 billion. The company's gross margin of 90.58% is exceptionally high and reflects the asset-light, fee-based nature of the brokerage and delegated authority model, where revenue is generated from commissions and underwriting fees rather than balance-sheet-intensive risk retention. However, the net margin of just 2.08% and operating margin of 20.49% reveal a wide gap between gross and net profitability, driven by compensation costs, acquisition-related amortization, and interest expense on the debt used to fund the company's aggressive M&A strategy. The forward EPS estimate of $2.70 (range $1.73 to $3.21) against trailing EPS of just $0.0096 implies an extraordinary earnings inflection is expected — a trajectory that, if delivered, would represent one of the sharpest margin expansions in the sector. Profitability is technically positive but razor-thin on a trailing basis, with trailing EPS of $0.0096 and a net margin of 2.08% that is well below what is typical for asset-light insurance brokers, which often convert 15-25% of revenue to net income. The ROE of 9.78% and ROA of 3.45% are modest and suggest that the company's substantial equity base — inflated by acquisition goodwill and intangibles — is not yet generating commensurate returns. The forward PE of 15.16 versus the trailing PE of 103.26 is the single most important fundamental signal in the dataset: it tells us the market expects earnings to roughly septuple, which is consistent with the forward EPS estimate of $2.70 versus trailing EPS near zero. The key question is whether this inflection is driven by organic operating leverage or by the lapsing of one-time acquisition and integration costs — the latter would be lower quality and less durable. The balance sheet carries meaningful leverage, with a debt-to-equity ratio of 5.45 that is high in absolute terms but partially mitigated by a current ratio of 7.51, indicating ample short-term liquidity. The company's dividend yield of 0.95% with a payout ratio of 98.33% is a red flag: the dividend is essentially consuming all trailing earnings, leaving no retained cash for debt reduction or organic investment, which means growth must be funded by cash flow from operations, incremental borrowing, or equity issuance. Free cash flow and cash flow statement data are not available in the provided dataset, so the sustainability of the dividend and the company's ability to deleverage cannot be fully assessed; however, the combination of high leverage, a near-100% payout ratio, and a PCF ratio of 10.21 suggests the company is not generating abundant discretionary cash. The investment case therefore hinges on whether the forward earnings inflection materializes and converts into genuine free cash flow that can service the debt load and fund the M&A pipeline without further balance-sheet strain.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is RYAN Overvalued?
Because trailing net income is positive but negligible — trailing EPS of $0.0096 and a trailing PE of 103.26 — the trailing PE is effectively meaningless as a valuation anchor, and the appropriate primary metric is the forward PE of 15.16, which is grounded in the consensus forward EPS estimate of $2.70. The gap between the trailing PE of 103.26 and the forward PE of 15.16 is enormous and implies the market is pricing in a near-total earnings recovery; if the forward estimate is achieved, the stock is cheap, but if it slips, the valuation support evaporates. The PEG ratio of -2.88 is negative and therefore not informative, reflecting the near-zero trailing earnings base rather than a genuine growth signal. On a peer-comparison basis, the stock's PS ratio of 2.15 and EV/Sales of 2.78 are moderate for a specialty insurance intermediary, but the PB ratio of 10.14 is elevated and reflects the goodwill-heavy balance sheet rather than a premium operating multiple. The EV/EBITDA of 12.38 is the most comparable metric to insurance brokerage peers, which typically trade in the 12-18x range; at 12.38x, Ryan Specialty sits at the low end of that band, suggesting the market is applying a discount for the company's leverage, integration risk, and the uncertainty around the earnings inflection. The forward PE of 15.16 versus a sector that often commands 18-22x forward earnings implies a discount of roughly 15-30%, which is difficult to justify given the company's 90.58% gross margin and 20.49% operating margin unless the market is skeptical of the forward EPS estimate. Historical ratio data is not available in the provided dataset, so the stock's current valuation cannot be benchmarked against its own multi-year PE or PS band. However, the price action itself provides context: at $37.01, the stock is 37.2% below its 52-week high of $58.94 and has a maximum drawdown of -49.66%, meaning the current multiple is almost certainly near the low end of its post-IPO historical range. The critical interpretive question is whether this represents a value opportunity — a high-quality, high-margin intermediary trading at a cyclical trough multiple — or a value trap, where the discount reflects structural concerns about specialty insurance pricing, M&A integration, and a balance sheet that leaves little room for error. Given the 98.33% payout ratio and 5.45 debt-to-equity ratio, the margin for error is thin, and the valuation will remain under pressure until the forward earnings inflection is demonstrated in reported results.
PE
103.3x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.4x
Enterprise Value Multiple
Investment Risk Disclosure
Ryan Specialty faces significant financial and operational risks. The company carries a debt-to-equity ratio of 5.45, which is high and reflects an aggressive M&A strategy funded by debt. Trailing net margin is only 2.08%, and trailing EPS is $0.0096, meaning profitability is razor-thin and heavily dependent on the anticipated earnings inflection. The dividend payout ratio of 98.33% leaves almost no retained earnings for debt reduction or organic investment, and with a PCF ratio of 10.21, free cash flow generation appears limited. If the forward EPS estimate of $2.70 is not achieved, the company could face liquidity pressures and may need to cut the dividend or raise equity, diluting shareholders.
Market and competitive risks are also pronounced. The stock trades at a forward PE of 15.16, which is a discount to peers, but this discount could persist if the market questions the sustainability of the earnings recovery. The beta of 0.605 suggests lower volatility than the market, but the stock has realized a -49.66% maximum drawdown, indicating that statistical beta understates tail risk. The specialty insurance intermediary space is competitive, and a softening rate environment could pressure commissions. Additionally, the recent news of a broad-based selloff in tech, gaming, and real estate (Feb 2026) highlights macro sensitivity, though RYAN's exposure is indirect. Regulatory changes affecting delegated underwriting authority could also pose headwinds.
In a worst-case scenario, if the earnings inflection fails to materialize and the company's leverage becomes unsustainable, the stock could retest its 52-week low of $29.28, representing a 20.9% decline from the current price of $37.01. If the dividend is cut and analysts downgrade the stock, the bear-case target could be even lower, potentially approaching the $29.28 low or below. The maximum drawdown of -49.66% from the 52-week high of $58.94 illustrates the potential severity of a downturn. Investors could lose approximately 21% to 50% of their investment if the bear case unfolds, depending on the severity of the earnings miss and balance sheet deterioration.
FAQ
The most severe risk is financial: a debt-to-equity ratio of 5.45 combined with a 98.33% dividend payout ratio leaves little room for error, and a failure to achieve the forward EPS estimate could lead to a dividend cut or liquidity crisis. Second is execution risk: the company must integrate acquisitions and expand net margin from 2.08% to levels that justify the forward EPS of $2.70. Third is market risk: the stock has a beta of 0.605, but its -49.66% max drawdown shows it can fall sharply in adverse conditions. Fourth is competitive risk: a softening specialty insurance rate environment could pressure commissions and growth. These risks are ranked from most to least severe, with the balance sheet being the primary concern.
Our 12-month forecast has three scenarios: a base case (55% probability) with a target range of $45-$55, assuming the forward EPS of $2.70 is achieved and net margin improves to 5-7%; a bull case (25% probability) with a target range of $58.94-$76.00, driven by multiple expansion and successful debt reduction; and a bear case (20% probability) with a target range of $29.28-$38.00, if the earnings inflection fails and the dividend is cut. The most likely scenario is the base case, which implies a return of 22-49% from the current price. The key assumption is that the company delivers on its forward earnings guidance, which would validate the current discount as an opportunity.
On a forward basis, RYAN appears undervalued. The forward PE of 15.16 is well below the 18-22x range typical for specialty insurance brokers, and the EV/EBITDA of 12.38 is at the low end of the 12-18x peer band. However, the trailing PE of 103.26 and PB ratio of 10.14 highlight the disparity between current earnings and future expectations. The market is pricing in a near-total earnings recovery, as evidenced by the forward EPS estimate of $2.70 versus trailing EPS of $0.0096. If the recovery materializes, the stock is cheap; if not, the valuation support evaporates. The discount is likely a reflection of leverage and execution risk rather than a structural impairment.
RYAN is a high-risk, high-reward proposition that is only suitable for investors with a strong stomach for volatility and a medium-to-long-term horizon. The stock trades at a forward PE of 15.16, a significant discount to peers, and analysts see 34.7% upside to their average target of $49.84. However, the company carries a debt-to-equity ratio of 5.45 and a dividend payout ratio of 98.33%, which leaves little margin for error. The bear case could see the stock retest its 52-week low of $29.28, representing a 21% decline. For those who believe in the earnings recovery story, the risk/reward is attractive, but position sizing should be conservative.
RYAN is better suited for long-term investors who can tolerate volatility and have a 2-3 year horizon, as the earnings recovery and debt reduction will take time to play out. The stock is not ideal for short-term trading due to its high short interest (short ratio of 7.86) and erratic price action, which can lead to sharp squeezes and reversals. The dividend yield of 0.95% is negligible and at risk of being cut, so income is not a reason to hold. A minimum holding period of 18-24 months is recommended to allow for the realization of the forward EPS estimate and potential multiple expansion. Short-term traders might find opportunities around earnings announcements, but the risk/reward is less favorable.